Northrup Hope, Aronow Mary E, Bebin E Martina, Bissler John, Darling Thomas N, de Vries Petrus J, Frost Michael D, Fuchs Zoë, Gosnell Elizabeth S, Gupta Nishant, Jansen Anna C, Jóźwiak Sergiusz, Kingswood J Chris, Knilans Timothy K, McCormack Francis X, Pounders Ashley, Roberds Steven L, Rodriguez-Buritica David F, Roth Jonathan, Sampson Julian R, Sparagana Steven, Thiele Elizabeth Anne, Weiner Howard L, Wheless James W, Towbin Alexander J, Krueger Darcy A
Department of Pediatrics, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas.
Retina Service, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts.
Pediatr Neurol. 2021 Oct;123:50-66. doi: 10.1016/j.pediatrneurol.2021.07.011. Epub 2021 Jul 24.
Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disease affecting multiple body systems with wide variability in presentation. In 2013, Pediatric Neurology published articles outlining updated diagnostic criteria and recommendations for surveillance and management of disease manifestations. Advances in knowledge and approvals of new therapies necessitated a revision of those criteria and recommendations.
Chairs and working group cochairs from the 2012 International TSC Consensus Group were invited to meet face-to-face over two days at the 2018 World TSC Conference on July 25 and 26 in Dallas, TX, USA. Before the meeting, working group cochairs worked with group members via e-mail and telephone to (1) review TSC literature since the 2013 publication, (2) confirm or amend prior recommendations, and (3) provide new recommendations as required.
Only two changes were made to clinical diagnostic criteria reported in 2013: "multiple cortical tubers and/or radial migration lines" replaced the more general term "cortical dysplasias," and sclerotic bone lesions were reinstated as a minor criterion. Genetic diagnostic criteria were reaffirmed, including highlighting recent findings that some individuals with TSC are genetically mosaic for variants in TSC1 or TSC2. Changes to surveillance and management criteria largely reflected increased emphasis on early screening for electroencephalographic abnormalities, enhanced surveillance and management of TSC-associated neuropsychiatric disorders, and new medication approvals.
Updated TSC diagnostic criteria and surveillance and management recommendations presented here should provide an improved framework for optimal care of those living with TSC and their families.
结节性硬化症(TSC)是一种常染色体显性遗传病,可影响多个身体系统,临床表现差异很大。2013年,《儿科神经学》发表了多篇文章,概述了疾病表现的最新诊断标准以及监测和管理建议。知识的进步和新疗法的获批使得有必要对这些标准和建议进行修订。
2012年国际TSC共识小组的主席和工作组联合主席受邀于2018年7月25日和26日在美国德克萨斯州达拉斯市举行的世界TSC会议上进行了为期两天的面对面会议。会议前,工作组联合主席通过电子邮件和电话与小组成员合作,以(1)回顾2013年出版物以来的TSC文献,(2)确认或修改先前的建议,以及(3)根据需要提供新的建议。
2013年报告的临床诊断标准仅做了两处修改:“多个皮质结节和/或放射状移行线”取代了更通用的术语“皮质发育异常”,硬化性骨病变重新被列为次要标准。遗传诊断标准得到重申,包括强调最近的发现,即一些TSC患者在TSC1或TSC2基因变异方面存在基因镶嵌现象。监测和管理标准的变化主要反映在更加重视脑电图异常的早期筛查、加强对TSC相关神经精神疾病的监测和管理以及新药物的获批。
本文提出的更新后的TSC诊断标准以及监测和管理建议应为TSC患者及其家庭的最佳护理提供一个更好的框架。